Zongertinib: Mechanism, Cancer Uses, and Side Effects

Zongertinib (brand name HERNEXEOS) is an oral, irreversible tyrosine kinase inhibitor designed to shut down HER2 signaling in cancer cells while leaving a closely related protein, EGFR, largely untouched. The U.S. Food and Drug Administration granted it accelerated approval in August 2025 for adults with previously treated HER2-mutant non-small-cell lung cancer, making it the first HER2-selective small-molecule drug cleared specifically for that disease.¹ That selectivity over EGFR is a big deal, because earlier drugs that block HER2 tend to hit EGFR too, producing side effects that limit how aggressively doctors can dose them.

How Zongertinib Locks Onto HER2

HER2 is a receptor protein sitting on the surface of cells. When it is active, it triggers a chain of signals that tell cells to grow and divide. In cancers with HER2 mutations or overexpression, that growth signal is stuck in the “on” position. Zongertinib works by forming a permanent chemical bond with a specific amino acid on HER2, cysteine 805, through a reactive part of its molecule called an acrylamide group.² Because that bond is irreversible, zongertinib doesn’t simply float away once it attaches. The HER2 protein is effectively disabled until the cell produces a new copy of it.

In laboratory testing, zongertinib showed strong activity against normal HER2 as well as a wide range of HER2 variants spanning different regions of the protein. Potency in cell models fell in the single-digit to low double-digit nanomolar range, meaning tiny concentrations were enough to stop HER2-driven cell growth. At the same time, cells that depended on normal EGFR were not affected at concentrations well above those needed to block HER2, with selectivity greater than 25-fold over EGFR.³ In other words, the drug hits its intended target at doses far lower than those that would interfere with EGFR.

Why Sparing EGFR Matters So Much

EGFR is one of HER2’s closest molecular relatives. The two proteins share enough structural similarity that most drugs designed to block one also block the other. That cross-reactivity causes real problems for patients. EGFR is essential for healthy skin, the lining of the gut, and other tissues. When you inhibit it, people develop rashes, severe diarrhea, and mouth sores. These side effects frequently force doctors to reduce the dose or stop the drug entirely, which undercuts the cancer-fighting benefit.

Earlier HER2-targeting small molecules like neratinib, tucatinib, and poziotinib all hit EGFR to varying degrees. Zongertinib was designed from the outset to avoid that trap. Preclinical experiments showed roughly 100-fold sparing of EGFR in proliferation assays comparing EGFR-dependent and HER2-dependent cells.² That wide margin gives room to use doses high enough to control HER2-driven tumors without dragging EGFR-related toxicities along for the ride.

Clinical Results in Previously Treated Lung Cancer

The trial that led to FDA approval, called Beamion LUNG-1, enrolled patients with advanced or metastatic non-small-cell lung cancer harboring HER2 mutations who had already received at least one prior line of therapy. In the main group of 75 patients receiving 120 mg of zongertinib daily, about 71% had a confirmed objective response, meaning their tumors shrank substantially on imaging. The median duration of those responses was roughly 14 months, and median progression-free survival reached about 12 months.⁴

Those numbers are striking for previously treated lung cancer, where response rates to standard chemotherapy typically run much lower. The trial also included smaller cohorts. One cohort of 31 patients saw a 48% confirmed response rate, and another of 20 patients saw a 30% response rate.⁴ The differences likely reflect variations in which specific HER2 alterations were present and how many prior treatments patients had received, though full details of each cohort’s composition are still being reported.

Moving Into the First-Line Setting

Most targeted therapies start their clinical life in patients who have run out of other options and then work their way forward to earlier-stage treatment if results hold up. Zongertinib followed that path. A separate analysis from Beamion LUNG-1 evaluated patients with advanced HER2-mutant lung cancer who had not received any prior systemic therapy. Among those patients, the confirmed objective response rate was about 76%, median duration of response was roughly 15 months, and median progression-free survival reached about 14 months.⁵

These first-line numbers are slightly better than the previously treated results, which is typical: patients whose tumors haven’t yet been pressured by other treatments tend to respond more robustly. The durability, with half of responders maintaining benefit past a year, suggests that zongertinib is not just producing brief tumor shrinkage but is holding cancers in check for a meaningful period. Whether this eventually translates into longer overall survival remains an open question that randomized phase III trials comparing zongertinib to standard first-line treatment will need to settle.

Side Effects and Tolerability

Given how much trouble EGFR-related toxicity causes with other HER2-targeting drugs, tolerability was a central question for zongertinib from the beginning. The cleanest safety snapshot comes from a bioavailability study in healthy male volunteers taking a single 240 mg dose, which is actually higher than the 120 mg dose used in the cancer trials. In that study, roughly two-thirds of participants experienced at least one treatment-related side effect, with headache being the most common. Other reported events included back pain, muscle pain, fatigue, nausea, and cough, all occurring in single participants and none reaching severe grades. No participant had a grade 3 or higher adverse event, and nobody stopped the study due to side effects.⁶

That healthy-volunteer snapshot is encouraging, but it represents a single dose in people without cancer. In ongoing cancer trials, patients take zongertinib daily for months or longer, and side-effect profiles often shift with prolonged exposure. The overall picture from the Beamion LUNG-1 trial has been described as having a promising safety profile, consistent with the EGFR-sparing design translating into fewer gut and skin problems than older agents.¹ Full safety data from the larger trial cohorts, including rates of liver enzyme elevation, cardiac effects, and any rare but serious events, will become clearer as the published record matures.

How Patients Experience Treatment Day to Day

Side-effect lists capture what doctors observe and record, but they don’t always reflect how patients feel. Patient-reported outcome data from Beamion LUNG-1 paint a more complete picture. Physical functioning scores improved quickly after starting zongertinib and held steady through at least nine treatment cycles. Specific cancer symptoms also improved. At the start of the trial, 43% of patients reported frequent fatigue; by cycle nine, that figure had fallen to just 3%. Coughing followed a similar trajectory, with 53% reporting no cough at all by cycle nine compared to 27% at the start. Frequent shortness of breath dropped from 23% to 3%.⁷

The side-effect burden patients reported was also remarkably low. At baseline, 7% said they were quite a bit or very much troubled by side effects. By cycle five that dropped to 3%, and by cycle nine it reached zero. That pattern, where patients feel better on treatment than they did before starting it, is not the norm in oncology. It reflects a drug that shrinks tumors (relieving the symptoms the cancer itself causes) without replacing those symptoms with harsh drug-related toxicity. Symptom improvement was seen both in patients whose tumors shrank and in those with stable disease, suggesting that even modest tumor control translated into quality-of-life gains.⁷

How the Body Absorbs and Clears Zongertinib

Zongertinib is taken as an oral tablet. After swallowing a dose, the drug reaches peak levels in the blood in about an hour, with a range of roughly half an hour to two hours. Oral bioavailability, meaning the fraction of the drug that actually makes it into your bloodstream, is about 76%, which is quite good for an oral cancer drug.⁸

The body breaks zongertinib down through several pathways in the liver, primarily oxidation along with some glucuronidation and glutathione conjugation. About 94% of the administered radioactive dose was recovered in total, with the overwhelming majority, around 93%, exiting through the feces. Only about 1% was found in urine. Unchanged zongertinib made up the largest share of what was circulating in the blood, accounting for roughly three-quarters of total drug-related material.⁸ The fact that fecal excretion dominates is relevant for patients with kidney problems: impaired kidney function is unlikely to cause major changes in how the drug is cleared, though liver function could matter more.

When Resistance Develops

As with virtually every targeted cancer therapy, tumors eventually find workarounds. Researchers have already begun mapping how HER2-mutant cancers escape zongertinib. The central vulnerability is the drug’s covalent binding site. Remember that zongertinib latches onto cysteine 805. One of the most straightforward resistance mechanisms is a secondary mutation that changes that cysteine to a serine (C805S), physically removing the amino acid the drug needs to grab. Other secondary mutations detected in tumor samples from patients who progressed on zongertinib include S783C, T862A, T798I, and L726F.⁹

These mutations were confirmed in laboratory models: when cells were engineered to carry both an activating HER2 mutation and one of these secondary changes, they became resistant to zongertinib. The C805S mutation is particularly interesting because it directly blocks the covalent bond formation. The other mutations likely reshape the protein’s binding pocket enough to weaken the drug’s grip. Understanding this landscape early is critical because it tells researchers what the next-generation drugs will need to overcome.

Combining Zongertinib with Antibody-Drug Conjugates

One of the more promising frontiers for zongertinib is using it alongside antibody-drug conjugates, which are a completely different class of HER2-targeting therapy. Drugs like trastuzumab deruxtecan (T-DXd) work by attaching a chemotherapy payload to an antibody that homes in on HER2-expressing cells. Because zongertinib blocks HER2 signaling directly while ADCs deliver their toxic payload through a binding-and-internalization pathway, the two approaches don’t step on each other mechanistically.¹⁰

In cell-line models, the combination of zongertinib with HER2-directed ADCs produced strong anti-tumor activity. Perhaps even more compelling, zongertinib was able to inhibit cancer cells that had already become resistant to T-DXd.¹¹ That’s a meaningful finding because T-DXd has become one of the most important drugs in HER2-driven cancers, and patients who progress on it currently have limited options. If clinical trials confirm the preclinical signal, sequencing or combining zongertinib with ADCs could expand the total time that patients benefit from HER2-targeted treatment. Clinical studies exploring these combinations are underway.

Beyond Lung Cancer

Zongertinib’s current FDA approval is limited to HER2-mutant non-small-cell lung cancer, but HER2 alterations show up in other tumor types as well. HER2 amplification or overexpression is a well-known driver in breast cancer and gastric cancer, and HER2 mutations appear at lower frequencies in cancers of the bladder, colon, and biliary tract, among others. The Beamion LUNG-1 trial was designed broadly to enroll patients with HER2-altered solid tumors, not just lung cancer.¹² Zongertinib is described as being developed for “advanced solid tumours with HER2 aberrations” broadly, not exclusively lung cancer.¹³

Whether the drug performs equally well in other HER2-driven cancers depends on several factors. In lung cancer, HER2 mutations are the primary driver, and the tumors tend to remain heavily dependent on that signal. In breast and gastric cancers, HER2 amplification rather than mutation is the more common alteration, and the biology may respond differently to a kinase inhibitor versus an antibody or ADC. The preclinical data showed activity across cell lines with diverse HER2 dependencies, including cells with HER2 overexpression and those harboring NRG1 gene fusions, suggesting the drug’s reach could be broad.³ But cell-line activity is a long way from proven clinical benefit, and each tumor type will need its own clinical evidence before zongertinib can be recommended outside of lung cancer.